Study of a new injection for weight loss in cancer
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests an investigational injection called INB301 to see if it can help reduce weight loss and improve appetite in people with cancer-related wasting (cachexia). It is a phase 1/2 study, so it is one of the first times the drug is given to people, and safety is a key goal.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a solid tumor cancer (like lung, colorectal, pancreatic, esophageal, or breast cancer) and have had treatment, with no major growth in the 28 days before starting.
- You must have lost at least 5% of your body weight in the past 6 months without trying (or 2% if your body mass index is low).
- Your blood test must show a GDF-15 level of 1200 pg/mL or higher (this is a protein linked to weight loss).
- You must be able to care for yourself (Eastern Cooperative Oncology Group score of 0, 1, or 2) and have an expected survival of at least 4 months.
- You cannot have other serious conditions like uncontrolled heart failure, active infections, or recent major surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new injection called GB18 in healthy adults to see if it is safe and how the body processes it. It may help researchers understand how to treat conditions that involve the immune system.
This study tests a new medicine (QLS2319) to see if it’s safe and can help people with cancer-related weight loss and muscle loss (cachexia). It’s for people whose daily activities aren’t severely limited by their cancer.
This study tests a new drug called GFS202A for people with advanced solid tumors who are experiencing weight loss or have a low body mass index (cachexia). The goal is to see if the drug is safe and can help improve appetite and weight.
This trial tests a new drug called JMT203 for people with cancer-related weight loss (cachexia). It aims to see if the drug can help prevent or reverse weight loss in patients with certain solid tumors who are also receiving or have recently completed anti-cancer therapy.
This Phase 1 trial tests a new drug called GB18 to help cancer patients who have experienced significant weight loss and muscle wasting—a condition called cancer cachexia. The drug works by targeting a specific protein involved in weight loss, and researchers want to learn if it can help patients regain weight and strength while also being safe.
This trial tests a new injection called SXRN for people with advanced cancer who have lost weight and appetite (cancer cachexia). The goal is to see if it is safe and might help improve weight and appetite.
Hear when a new Cancer Cachexia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.